The immunodiagnostics specialist’s biomarker discovery platform SeroTag is being used to “explore the baseline and on-treatment autoantibody profiles as biomarkers in patients that received cancer immunotherapy”.
The timeline for the project has not changed, with initial results to be provided to Roche within three months of completion in November.
"Our ongoing relationship with Roche is providing us with the opportunity to further contribute to the understanding of individual patient responses to immunotherapy through immune profiling,” Oncimmune chief executive, Dr Adam Hill said in a statement.
While financial details weren’t provided, Oncimmune said in May the contract involved a substantial upfront payment.
“Importantly, we are delighted to see the substantial value that Oncimmune can contribute to major pharmaceutical and biotechnology companies,” said CEO Hill.
“With the number of partners utilising our ImmunoINSIGHTS service continuing to grow, I look forward to announcing future projects in the coming few months."